Last reviewed · How we verify
Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel Chemotherapy (GYM-TASTE)
This observational study aims to evaluate chemotherapy-induced taste alterations, sarcopenia, and malnutrition in patients with gynecologic malignancies (ovarian, fallopian tube, and endometrial cancer) treated with standard carboplatin and paclitaxel. Eligible patients will receive six cycles of chemotherapy (carboplatin area under the curve \[AUC\] 5 + paclitaxel 175-200 mg/m², every 21 days), and assessments will be performed at baseline (before chemotherapy), after the 3rd cycle (\~9 weeks), and after the 6th cycle (\~18 weeks). Validated tools will be used, including the Chemotherapy-Induced Taste Alteration Scale (CITAS, Turkish validated, range 18-90; higher scores indicate greater severity of dysgeusia), the Patient-Generated Subjective Global Assessment (PG-SGA, Turkish validated, range 0-35; higher scores indicate worse nutritional status), and Computed Tomography (CT)-based Skeletal Muscle Index (SMI) at the L3 vertebra level.
Details
| Lead sponsor | Ankara Etlik City Hospital |
|---|---|
| Status | COMPLETED |
| Enrolment | 102 |
| Start date | Fri Mar 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Ovarian Cancer (OvCa)
- Fallopian Tube Cancers
- Endometrial Cancer
- Chemotherapy-Induced Taste Alteration
- Cancer-Associated Malnutrition
- Cancer-Associated Sarcopeni
Interventions
- Standard Chemotherapy (Carboplatin-Paclitaxel)
Countries
Turkey (Türkiye)